Aclarion Announces Reverse Stock Split
BROOMFIELD, CO, Jan. 02, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq:ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Thursday January 4, 2024, it will complete a 1-for-16 reverse stock split of its common stock.
Related news for (ACON)
- First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
- Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site
- Aclarion Announces Texas Back Institute as New CLARITY Trial Site
- Aclarion Welcomes Advocate Health as CLARITY Trial Site
- Aclarion Announces Commercial Agreement with Spine Institute of Louisiana